A study investigating the cardiovascular responses to nitroglycerin in migraine found that migraineurs who developed a migraine-like attack in response to nitroglycerin demonstrated greater systemic cardiovascular responses compared with non-headache controls.
A study investigating the cardiovascular responses to nitroglycerin in migraine found that migraineurs who developed a migraine-like attack in response to nitroglycerin demonstrated greater systemic cardiovascular responses compared with non-headache controls.
The research, published by Cephalalgia, involved 16 women with migraine and without aura to 10 age- and gender-matched controls without headache. Intravenous nitroglycerin was administered in all patients and finger photoplethysmography was used to evaluate the cardiovascular parameters before, during, and after nitroglycerin infusion.
“Some studies have suggested ictal and interictal functional changes in the systemic circulation in migraine. Interestingly, migraineurs also have an increased rate of vasovagal syncope (VVS), which partly explains the white matter abnormalities found in a population-based study,” noted the authors. “Nitroglycerin may also provoke migraine attacks, but only in migraineurs. Nitroglycerin is de-nitrated to nitric oxide (NO) and vasoactive S-nitrosothiols. Both substances cause vasodilation through activation of cytoplasmic guanylate cyclase, which increases intracellular guanosine-3’,5’-monophosphate (cGMP) and cytosolic calcium.”
The analysis revealed that nitroglycerin provoked a migraine-like attack in 81.2% of migrainers but not in the controls. In addition, migraineurs who later developed a migraine-like attack showed different responses in all parameters compared to the controls, including: decreases in cardiac output and stroke volume were more rapid and longer lasting, heart rate increased, and the average arterial pressure and total peripheral resistance were higher and decreased steeply after the initial increase, according to the results.
“Using continuous photoplethysmography, we showed that intravenous nitroglycerin administration induced a faster and more prolonged decrease in stroke volume and cardiac output, a steep decrease in total peripheral resistance after an initial increase, a slightly higher mean arterial pressure, and a sustained increase in heart rate in migraine participants in whom an attack developed later,” explained the authors. “The enhanced response of the systemic circulation to nitroglycerin in migraineurs suggest that the systemic vasculature is more susceptible to its (vasodilatory) effects.”
The researchers concluded that the stronger systemic cardiovascular responses in migraine suggested increased systemic sensitivity to vasodilators which may be due to insufficient autonomic compensatory mechanisms. Further studies may be needed to investigate the differences between attack-onset subgroups, according to the authors.
Reference
Van Oosterhout W, Schoonman G, et al. Abnormal cardiovascular response to nitroglycerin in migraine [published online October 9, 2019]. Cephalalgia. doi: 10.1177/0333102419881657.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More